Boncresa Injection, Solution
NDC Package 70121-2702-1

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

Boncresa (denosumab-mobz) injection is denosumab is used to treat bone loss (osteoporosis) in people who have a high risk of getting fractures. This formulation utilizes a injection, solution delivery system. Marketed by Amneal Pharmaceuticals Llc, this product is identified by NDC 70121-2702 and is authorized under FDA application BLA761456.

Identification & Billing

NDC Package Code
70121-2702-1
Package Description
1 SYRINGE in 1 CARTON / 1 mL in 1 SYRINGE
Product Code
70121-2702
11-Digit Billing Format
70121270201
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Boncresa
Non-Proprietary Name
Denosumab-mobz
Substance Name
Denosumab
Dosage Form
Injection, Solution - A liquid preparation containing one or more drug substances dissolved in a suitable solvent or mixture of mutually miscible solvents that is suitable for injection.
Administration Route
Subcutaneous - Administration beneath the skin; hypodermic. Synonymous with the term SUBDERMAL.
Active Ingredient(s)
DENOSUMAB 60 mg/mL
Pharmacologic Class
Usage Information
Denosumab is used to treat bone loss (osteoporosis) in people who have a high risk of getting fractures. Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases after menopause (in women), as you age, if someone in your family has osteoporosis, or if you take certain medications (such as prednisone) for long periods. This medication works by slowing bone loss to help maintain strong bones and reduce the risk of broken bones (fractures). Denosumab belongs to a class of drugs called monoclonal antibodies. It prevents certain cells in the body (osteoclasts) from breaking down bone.

Regulatory & Marketing

Labeler Name
Amneal Pharmaceuticals Llc
Product Type
Human Prescription Drug
FDA Application #
BLA761456
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
12-23-2025
Listing Expiration
12-31-2026
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70121-2702-1 identifies a specific commercial package of 1 syringe in 1 carton / 1 ml in 1 syringe of Boncresa, a human prescription drug labeled by Amneal Pharmaceuticals Llc. This injection, solution is formulated for subcutaneous use and contains denosumab as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Amneal Pharmaceuticals Llc on December 23, 2025. The current certification is valid through December 31, 2026.

What are the primary indications for this medication?

Denosumab is used to treat bone loss (osteoporosis) in people who have a high risk of getting fractures. Osteoporosis causes bones to become thinner and break more easily. Your chance of developing osteoporosis increases after menopause (in women), as you age, if someone in your family has osteoporosis, or if you take certain medications (such as prednisone) for long periods. This medication works by slowing bone loss to help maintain strong bones and reduce the risk of broken bones (fractures). Denosumab belongs to a class of drugs called monoclonal antibodies. It prevents certain cells in the body (osteoclasts) from breaking down bone.

How is this Amneal Pharmaceuticals Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70121270201. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
70121-2702-1
11-Digit CMS (5-4-2)
70121-2702-01

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.